Abstract
Women in Cardiovascular Clinical Trials Between 1980 and 2000, the age-adjusted death rate due to coronary heart disease (CHD) decreased by 48%. The optimization of medical therapies (OMT) and revascularization procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) has accounted for 50% of the decline. While mortality rates for CHD have not declined equally for men and women, recent randomized clinical trials have not addressed gender differences regarding the efficacy of therapeutic interventions. Historically, women have been underrepresented in clinical trials of cardiovascular disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
